Skip to main content
Premium Trial:

Request an Annual Quote

Trinean Licenses Microfluidic IP from PerkinElmer's Caliper Business

NEW YORK (GenomeWeb News) – Belgian spectrophotometer firm Trinean today said it has licensed intellectual property covering microfluidic technologies from PerkinElmer's Caliper Life Sciences business directed at UV-VIS quantification analysis.

The license allows Trinean to design and develop microfluidic cartridges and instruments for the UV/VIS quantification of light-absorbing substances for certain life science applications, Trinean said. Further details of the deal were not disclosed.

"The combined IP from Trinean and PerkinElmer will boost the expansion of our platform for DNA, RNA, and protein quantification and quality control," Philippe Stas, CEO of Trinean, said in a statement.

"The use of microfluidics for UV/Vis spectrometry is an exciting market development,"
Kevin Hrusovsky, life sciences president for PerkinElmer, added. "We continue to leverage our microfluidics portfolio through licensing collaborations such as our agreement with Trinean to extend our market reach and create additional revenue opportunities."

Caliper and Trinean inked a deal two years ago giving Caliper exclusive rights to distribute the Belgian company's automated UV/Vis spectral analysis platform in North America.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.